Metformin in the Era of New Antidiabetics

References

• Wang L , GaoP, ZhangMet al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA, 317(24), 2515 (2017).
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas (9th Edition). (2019). https://www.diabetesatlas.org/en/
   Google Scholar
• American Diabetes Association . 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Suppl. 1), S14–S31 (2020).
   PubMed Web of Science ®Google Scholar
• Guillausseau P-J , MeasT, VirallyM, Laloi-MichelinM, MédeauV, KevorkianJ-P. Abnormalities in insulin secretion in Type 2 diabetes mellitus. Diabetes Metab., 34, S43–S48 (2008).
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration , SarwarN, GaoPet al.Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet Lond. Engl., 375(9733), 2215–2222 (2010).
   PubMed Web of Science ®Google Scholar
• Sasaki A , HoriuchiN, HasegawaK, UeharaM. Mortality and causes of death in Type 2 diabetic patients: a long-term follow-up study in Osaka District, Japan. Diabetes Res. Clin. Pract., 7(1), 33–40 (1989).
   PubMed Web of Science ®Google Scholar
• Zinman B , WannerC, LachinJMet al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N. Engl. J. Med., 373(22), 2117–2128 (2015).
   PubMed Web of Science ®Google Scholar
• Neal B , PerkovicV, MahaffeyKWet al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N. Engl. J. Med., 377(7), 644–657 (2017).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , RazI, BonacaMPet al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med., 380(4), 347–357 (2019).
   PubMed Web of Science ®Google Scholar
• Zelniker TA , WiviottSD, RazIet al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in Type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 393(10166), 31–39 (2019).
   PubMed Web of Science ®Google Scholar
• Cannon CP , PratleyR, Dagogo-JackSet al. Cardiovascular outcomes with ertugliflozin in Type 2 diabetes. N. Engl. J. Med., 383(15), 1425–1435 (2020).
   PubMed Web of Science ®Google Scholar
• McMurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381(21), 1995–2008 (2019).
   PubMed Web of Science ®Google Scholar
• Marso SP , DanielsGH, Brown-FrandsenKet al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med., 375(4), 311–322 (2016).
   PubMed Web of Science ®Google Scholar
• Marso SP , BainSC, ConsoliAet al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med., 375(19), 1834–1844 (2016).
   PubMed Web of Science ®Google Scholar
• Gerstein HC , ColhounHM, DagenaisGRet al. Dulaglutide and cardiovascular outcomes in Type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 394(10193), 121–130 (2019).
   PubMed Web of Science ®Google Scholar
• Hernandez AF , GreenJB, JanmohamedSet al. Albiglutide and cardiovascular outcomes in patients with Type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 392(10157), 1519–1529 (2018).
   PubMed Web of Science ®Google Scholar
• Zelniker TA , WiviottSD, RazIet al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in Type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation, 139(17), 2022–2031 (2019).
   PubMed Web of Science ®Google Scholar
• Husain M , BirkenfeldAL, DonsmarkMet al. Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med., 381(9), 841–851 (2019).
   PubMed Web of Science ®Google Scholar
• Pasternak B , WintzellV, MelbyeMet al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study. BMJ., 369, m1186 (2020).
   PubMed Web of Science ®Google Scholar
• Pasternak B , WintzellV, EliassonBet al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care, 43(6), 1326–1335 (2020).
   PubMed Web of Science ®Google Scholar
• Cosentino F , GrantPJ, AboyansVet al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J., 41(2), 255–323 (2020).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Suppl. 1), S98–S110 (2020).
   PubMedGoogle Scholar
• Scheen AJ . Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 30(5), 359–371 (1996).
   PubMed Web of Science ®Google Scholar
• Graham GG , PuntJ, AroraMet al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 50(2), 81–98 (2011).
   PubMed Web of Science ®Google Scholar
• Foretz M , GuigasB, ViolletB. Understanding the glucoregulatory mechanisms of metformin in Type 2 diabetes mellitus. Nat. Rev. Endocrinol., 15(10), 569–589 (2019).
   PubMed Web of Science ®Google Scholar
• Wu T , HorowitzM, RaynerCK. New insights into the anti-diabetic actions of metformin: from the liver to the gut. Expert Rev. Gastroenterol. Hepatol., 11(2), 157–166 (2017).
   PubMed Web of Science ®Google Scholar
• Tucker G , CaseyC, PhillipsP, ConnorH, WardJ, WoodsH. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol., 12(2), 235–246 (1981).
   PubMed Web of Science ®Google Scholar
• Wu T , ThazhathSS, BoundMJ, JonesKL, HorowitzM, RaynerCK. Mechanism of increase in plasma intact GLP-1 by metformin in Type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?Diabetes Res. Clin. Pract., 106(1), e3–e6 (2014).
   PubMed Web of Science ®Google Scholar
• Wilcox T , DeBlock C, SchwartzbardArthur Z, NewmanJonathan D. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists. J. Am. Coll. Cardiol., 75(16), 1956–1974 (2020).
   PubMed Web of Science ®Google Scholar
• Garber AJ , DuncanTG, GoodmanAM, MillsDJ, RohlfJL. Efficacy of metformin in Type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med., 103(6), 491–497 (1997).
   PubMed Web of Science ®Google Scholar
• Piera-Mardemootoo C , LambertP, FaillieJ-L. Efficacy of metformin on glycemic control and weight in drug-naive Type 2 diabetes mellitus patients: a systematic review and meta-analysis of placebo-controlled randomized trials. Thérapie doi: https://doi.org/10.1016/j.therap.2018.01.006 (2018) ( Epub ahead of print).
   PubMedGoogle Scholar
• Hirst JA , FarmerAJ, AliR, RobertsNW, StevensRJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care, 35(2), 446–454 (2012).
   PubMed Web of Science ®Google Scholar
• Saenz A , Fernandez-EstebanI, MataixA, AusejoM, RoqueM, MoherD. Metformin monotherapy for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (3), CD002966 (2005).
   PubMed Web of Science ®Google Scholar
• Hallsten K , VirtanenKA, LonnqvistFet al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed Type 2 diabetes. Diabetes, 51(12), 3479–3485 (2002).
   PubMed Web of Science ®Google Scholar
• Malin SK , KashyapSR. Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes., 21(5), 323–329 (2014).
   PubMedGoogle Scholar
• Mach F , BaigentC, CatapanoALet al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 41(1), 111–188 (2020).
   PubMed Web of Science ®Google Scholar
• Xu T , BrandmaierS, MessiasACet al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with Type 2 diabetes. Diabetes Care, 38(10), 1858–1867 (2015).
   PubMed Web of Science ®Google Scholar
• Jager JD , KooyA, LehertPet al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in Type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med., 257(1), 100–109 (2005).
   PubMed Web of Science ®Google Scholar
• Preiss D , LloydSM, FordIet al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol., 2(2), 116–124 (2014).
   PubMed Web of Science ®Google Scholar
• Lin SH , ChengPC, TuST, HsuSR, ChengYC, LiuYH. Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed Type 2 diabetes mellitus: a cohort study. PeerJ., 6, e4578 (2018).
   PubMed Web of Science ®Google Scholar
• Wulffelé MG , KooyA, de ZeeuwD, StehouwerCDA, GansevoortRT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in Type 2 diabetes mellitus: a systematic review. J. Intern. Med., 256(1), 1–14 (2004).
   PubMed Web of Science ®Google Scholar
• Saran R , RobinsonB, AbbottKCet al. US renal data system 2018 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis., 73(3), A7–A8 (2019).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . 11. Microvascular complications and foot care: standards of medical care in diabetes−2020. Diabetes Care, 43(Suppl. 1), S135–S151 (2020).
   PubMedGoogle Scholar
• Kwon S , KimYC, ParkJYet al. The long-term effects of metformin on patients with Type 2 diabetic kidney disease. Diabetes Care, 43(5), 948–955 (2020).
   PubMed Web of Science ®Google Scholar
• Lalau J-D , KajbafF, BennisY, Hurtel-LemaireA-S, BelpaireF, BroeMED. Metformin treatment in patients with Type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care, 41(3), 547–553 (2018).
   PubMed Web of Science ®Google Scholar
• Rajani R , Pastor-SolerNM, HallowsKR. Role of AMP-activated protein kinase in kidney tubular transport, metabolism, and disease. Curr. Opin. Nephrol. Hypertens., 26(5), 375–383 (2017).
   PubMed Web of Science ®Google Scholar
• Salpeter SR , BuckleyNS, KahnJA, SalpeterEE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med., 121(2), 149–157.e2 (2008).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . 3. Prevention or delay of Type 2 diabetes: standards of medical care in diabetes—2020. Diabetes Care, 43(Suppl. 1), S32–S36 (2020).
   PubMedGoogle Scholar
• Griffin SJ , BethelMA, HolmanRRet al. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol. Assess. Winch. Engl., 22(18), 1–64 (2018).
   Web of Science ®Google Scholar
• Luo F , DasA, ChenJ, WuP, LiX, FangZ. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc. Diabetol., 18(1), 54 (2019).
   PubMedGoogle Scholar
• Petrie JR , ChaturvediN, FordIet al. Cardiovascular and metabolic effects of metformin in patients with Type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol., 5(8), 597–609 (2017).
   PubMed Web of Science ®Google Scholar
• Seifarth C , SchehlerB, SchneiderHJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp. Clin. Endocrinol. Diabetes , 121(1), 27–31 (2013).
   PubMed Web of Science ®Google Scholar
• Nestler JE , JakubowiczDJ, EvansWS, PasqualiR. Effects of Metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med., 338(26), 1876–1880 (1998).
   PubMed Web of Science ®Google Scholar
• Lord JM , FlightIHK, NormanRJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. (3), CD003053 (2003).
   PubMedGoogle Scholar
• Heckman-Stoddard BM , DeCensiA, SahasrabuddheVV, FordLG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia, 60(9), 1639–1647 (2017).
   PubMed Web of Science ®Google Scholar
• Aljofan M , RiethmacherD. Anticancer activity of metformin: a systematic review of the literature. Future Sci. OA, 5(8), FSO410 (2019).
   PubMed Web of Science ®Google Scholar
• Vancura A , BuP, BhagwatM, ZengJ, VancurovaI. Metformin as an anticancer agent. Trends Pharmacol. Sci., 39(10), 867–878 (2018).
   PubMed Web of Science ®Google Scholar
• Pereira FV , MeloACL, LowJSet al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget., 9(40), 25808–25825 (2018).
   PubMedGoogle Scholar
• Coyle C , CaffertyFH, ValeC, LangleyRE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 27(12), 2184–2195 (2016).
   PubMed Web of Science ®Google Scholar
• Saraei P , AsadiI, KakarMA, Moradi-KorN. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag. Res., 11, 3295–3313 (2019).
   PubMed Web of Science ®Google Scholar
• Lv Z , GuoY. Metformin and its benefits for various diseases. Front. Endocrinol., 11, 191 (2020).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet, 352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Holman RR , PaulSK, BethelMA, MatthewsDR, NeilHAW. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med., 359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Kooy A , de JagerJ, LehertPet al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with Type 2 diabetes mellitus. Arch. Intern. Med., 169(6), 616–625 (2009).
   PubMedGoogle Scholar
• Hong J , ZhangY, LaiSet al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with Type 2 diabetes and coronary artery disease. Diabetes Care, 36(5), 1304–1311 (2013).
   PubMed Web of Science ®Google Scholar
• Maruthur NM , TsengE, HutflessSet al. Diabetes medications as monotherapy or metformin-based combination therapy for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med., 164(11), 740–751 (2016).
   PubMed Web of Science ®Google Scholar
• Han Y , XieH, LiuY, GaoP, YangX, ShenZ. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc. Diabetol., 18(1), 96 (2019).
   PubMedGoogle Scholar
• Bergmark Brian A , BhattDeepak L, McGuireDarren Ket al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction. Circulation, 140(12), 1004–1014 (2019).
   PubMed Web of Science ®Google Scholar
• Roumie CL , ChipmanJ, MinJYet al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and Reduced kidney function. JAMA1–11 (2019).
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C , MargulisAV, PladevallMet al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc. Disord., 14, 129 (2014).
   PubMed Web of Science ®Google Scholar
• Tseng C . Metformin use is associated with a lower risk of hospitalization for heart failure in patients with Type 2 diabetes mellitus: a retrospective cohort analysis. J. Am. Heart Assoc., 8(21), e011640 (2019).
   PubMed Web of Science ®Google Scholar
• Vantrimpont P , RouleauJL, WunC-Cet al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study fn1fn1 this study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J. Am. Coll. Cardiol., 29(2), 229–236 (1997).
   PubMed Web of Science ®Google Scholar
• Williams B , ManciaG, SpieringWet al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J., 39(33), 3021–3104 (2018).
   PubMed Web of Science ®Google Scholar
• Wulffelé MG , KooyA, LehertPet al. Combination of insulin and metformin in the treatment of Type 2 diabetes. Diabetes Care, 25(12), 2133–2140 (2002).
   PubMed Web of Science ®Google Scholar
• Cook MN , GirmanCJ, SteinPP, AlexanderCM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet. Med. J. Br. Diabet. Assoc., 24(4), 350–358 (2007).
   PubMed Web of Science ®Google Scholar
• Matthews DR , PaldániusPM, ProotPet al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed Type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet Lond. Engl., 394(10208), 1519–1529 (2019).
   PubMed Web of Science ®Google Scholar
• Rosenstock J , ChuckL, González-OrtizMet al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve Type 2 diabetes. Diabetes Care, 39(3), 353–362 (2016).
   PubMed Web of Science ®Google Scholar
• Henry RR , MurrayAV, MarmolejoMH, HennickenD, PtaszynskaA, ListJF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for Type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract., 66(5), 446–456 (2012).
   PubMed Web of Science ®Google Scholar
• Hadjadj S , RosenstockJ, MeinickeT, WoerleHJ, BroedlUC. Initial combination of empagliflozin and metformin in patients with Type 2 diabetes. Diabetes Care, 39(10), 1718–1728 (2016).
   PubMed Web of Science ®Google Scholar
• Gu J , MengX, GuoYet al. The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. Sci. Rep., 6(1), 32714 (2016).
   PubMedGoogle Scholar
• Freeman VS . Glucose and hemoglobin A 1c. Lab. Med., 45(1), e21–e24 (2014).
   Google Scholar
• 6. Glycemic targets: standards of medical care in diabetes—2020. 43, 11 (2020).
   Google Scholar
• Nathan DM . The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 Years: overview. Diabetes Care, 37(1), 9–16 (2014).
   PubMed Web of Science ®Google Scholar
• Vasilakou D , KaragiannisT, AthanasiadouEet al. Sodium-glucose cotransporter 2 inhibitors for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med., 159(4), 262–274 (2013).
   PubMed Web of Science ®Google Scholar
• Hinnen D . Glucagon-like peptide 1 receptor agonists for Type 2 diabetes. Diabetes Spectr., 30(3), 202–210 (2017).
   PubMedGoogle Scholar
• Zelniker Thomas A , BraunwaldE. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J. Am. Coll. Cardiol., 75(4), 422–434 (2020).
   PubMed Web of Science ®Google Scholar
• Sposito AC , BerwangerO, de CarvalhoLSF, SaraivaJFK. GLP-1RAs in Type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc. Diabetol., 17(1), 157 (2018).
   PubMedGoogle Scholar
• Salpeter SR , GreyberE, PasternakGA, SalpeterPosthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (1), CD002967 (2010).
   Web of Science ®Google Scholar
• Longato E , CamilloBD, SparacinoG, GubianL, AvogaroA, FadiniGP. Cardiovascular outcomes of Type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res. Care., 8(1), e001451 (2020).
   PubMed Web of Science ®Google Scholar
• Chow CK , MengQ. Polypills for primary prevention of cardiovascular disease. Nat. Rev. Cardiol., 16(10), 602–611 (2019).
   PubMed Web of Science ®Google Scholar